Primatene Mist Availability Not “Essential,” Advisory Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Primatene Mist could face market withdrawal; FDA advisory panel considered whether mild asthma is a condition for which OTC treatments should remain available.